Sorted By Test Name - Mayo Medical Laboratories

5368
CMA
9278
autoantibodies can be detected in the patient's serum, but extensive data demonstrate that direct detection
of immunologically bound immunoglobulin (usually IgG) is considerably more sensitive for autoantibody
detection. The method consists of an elution step followed by solid-phase enzyme-linked immunoassay,
which not only concentrates the cell-bound antibodies, but identifies the target glycoproteins against
which they are directed. In most studies of autoimmune thrombocytopenia, the majority (approximately
80%) of detected autoantibodies were directed to the platelet glycoprotein IIb/IIIa and, more rarely, to
other glycoproteins such as Ib/IX (approximately 11%) or Ia/IIa.
Useful For: Diagnosis of idiopathic (autoimmune) thrombocytopenia purpura Diagnosis of immune
thrombocytopenia associated with systemic lupus erythematosus or other disorders associated with
autoimmune phenomena
Interpretation: A positive test, particularly to GP IIB/IIIa or Ib/IX, in the presence of
thrombocytopenia (not explained by other findings) is consistent with idiopathic (autoimmune)
thrombocytopenic purpura. Similarly, a positive test in a thrombocytopenic patient with systemic lupus
erythematosus is consistent with an autoimmune cause. Patients who are septic may also have a positive
test with reactivity against most glycoproteins. Presence of reactivity to some glycoproteins has no clearly
established clinical significance.
Reference Values:
An interpretive report will be provided.
Clinical References: 1. McMillan R, Tani P, Millard F, et al: Platelet-associated and plasma
anti-glycoprotein autoantibodies in chronic ITP. Blood 1987;70:1040-1045 2. Moore SB, Wick MR,
Richardson LM: Immune thrombocytopenias: tests for platelet antibodies. Mayo Clin Proc
1984;59:860-863 3. Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C: Monoclonal antibody-specific
immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive
antibodies. Blood 1987;70:1722-1726 3. Moore SB, DeGoey SR: Serum platelet antibody testing:
evaluation of solid-phase enzyme immunoassay and comparison with indirect immunofluorescence. Am J
Clin Pathol 1998;109:190-195
Central Nervous System Consultation, Autopsy
Reference Values:
This request will be processed as a consultation. Appropriate dissection will be performed and an
interpretive report provided.
Centromere Antibodies, IgG, Serum
Clinical Information: Centromere antibodies occur primarily in patients with the calcinosis,
Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasis (CREST) syndrome
variant of systemic sclerosis (scleroderma). CREST syndrome is characterized by the following clinical
features: calcinosis, Raynaud's phenomenon, esophageal hypomotility, sclerodactyly, and
telangiectasia.(1) Centromere antibodies were originally detected by their distinctive pattern of
fine-speckled nuclear staining on cell substrates used in the fluorescent antinuclear antibody test.(2) In
subsequent studies, centromere antibodies were found to react with several centromere proteins of 18
kDa, 80 kDa, and 140 kDa named as CENP-A, CENP-B, and CENP-C, respectively.(3) Several putative
epitopes associated with these autoantigens have been described. The CENP-B antigen is believed to be
the primary autoantigen and is recognized by all sera that contain centromere antibodies.
Useful For: Evaluating patients with clinical signs and symptoms compatible with systemic sclerosis
including skin involvement, Raynaudâ€s phenomenon, and arthralgias As an aid in the diagnosis of
calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and telangiectasis (CREST)
syndrome
Interpretation: In various reported clinical studies, centromere antibodies occur in 50% to 96% of
patients with calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclerodactyly, and
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 420